A peer-reviewed clinical review published in Integr Med examines peptide therapeutics—including BPC-157, thymosin alpha-1, thymosin beta-4, and growth hormone secretagogues—as potential adjunctive treatments for autoimmune thyroid disorders like Hashimoto’s that persist despite hormone normalization. The review acknowledges mechanistic rationale for peptide effects on immune signaling, inflammation, and tissue repair, but emphasizes that current evidence is primarily preclinical and exploratory, with no large randomized thyroid-specific trials yet completed. The authors call for rigorous clinical investigation to establish safety and efficacy, noting substantial evidence gaps and that peptide use in thyroid care remains investigational.
For your business
BPC-157 shows preclinical immune-modulatory signals relevant to autoimmune thyroid cases, but no human trials yet confirm thyroid-specific benefit.